Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

AIMS Allergy and Immunology is a prestigious open access journal dedicated to advancing knowledge in the fields of allergy and immunology. Published by the American Institute of Mathematical Sciences (AIMS), this journal provides a vibrant platform for researchers, practitioners, and scholars to share groundbreaking findings and insights. Recognized for its commitment to disseminating high-quality research since its inception in 2017, AIMS Allergy and Immunology contributes significantly to the understanding of complex immunological mechanisms and allergic responses, thus playing a pivotal role in enhancing clinical practices and therapeutic strategies. With its ISSN 2575-615X, the journal aims to facilitate a robust exchange of ideas and promote collaboration within the scientific community. Researchers and practitioners are encouraged to access the latest studies and reviews, which are all freely available online, ensuring that vital information reaches a global audience without barriers. Together, we can tackle the challenges posed by allergies and immune disorders through rigorous scientific inquiry and innovation.

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

Clinical and Experimental Vaccine Research, an esteemed journal published by the Korean Vaccine Society, serves as a vital platform for disseminating groundbreaking research in the fields of Immunology, Infectious Diseases, and Public Health. Since its inception in 2012, this open-access journal has been committed to advancing knowledge and fostering collaboration among professionals dedicated to vaccine development and evaluation. With an impactful presence and a Q3 ranking in several categories on the Scopus index, it reflects a robust commitment to quality, evidenced by its placement within the 41st to 59th percentiles across multiple disciplines related to medicine and health. Situated in Seoul, South Korea, at the Department of Pediatrics, Yonsei University Severance Children's Hospital, the journal not only provides a crucial resource for researchers and practitioners but also enhances the global discourse on vaccination strategies and public health interventions. By contributing to the ongoing dialogue in vaccine research, this journal plays an essential role in shaping future health policies and practices.

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.